Cervical Cancer :: Gardasil caervical cancer vaccine in Australia !
In Australia, there is a debate over the future roll-out of the new cervical cancer vaccine, Gardasil.
Company
Osteosarcoma :: IDM Pharma’s Mepact, mifamurtide – Junovan in the Treatment of Osteosarcoma
IDM Pharma (NASDAQ:IDMI) announced today that the company has submitted a Marketing Authorization Application (MAA) in eCTD format (electronic common technical document) to the European Medicines Agency (EMEA) for Mepact (mifamurtide for injection), requesting approval for its use in the treatment of patients with newly diagnosed resectable high-grade osteosarcoma following surgical resection in combination with post-operative multi-agent chemotherapy. This announcement follows the October 25, 2006 submission of a New Drug Application (NDA) for Junovan (mifamurtide for injection) to the Food and Drug Administration (FDA) in the United States.
Health :: Colorado Company to Sell Medical Food Products Based on Wake Forest Discovery
A Colorado-based company is launching a line of ‘medical- food’ products for the dietary management of asthma, eczema and other allergic conditions based on discoveries by Floyd H. ‘Ski’ Chilton, Ph.D., of Wake Forest University Health Sciences (WFUHS).
Health :: DSM to make weight management personal with IntegraGen
DSM is continuing to build its personalised nutrition capabilities with its venturing arm making a ?2m investment in IntegraGen, and a collaboration with the French biotech to apply its genetic tests to weight management products.
Leukemia :: When Gleevec is not enough
Researchers at the Jackson Laboratory, in collaboration with scientists at Bristol-Myers Squibb Oncology, discovered is that imatinib does not inactivate all BCR-ABL signaling pathways in the cascade. Proteins called SRC kinases are still activated by BCR-ABL in imatinib-treated mouse leukemic cells. Treatment with dasatinib, which inhibits the SRC proteins as well as BCR-ABL, was not only more effective for CML, but also led to complete B-ALL remission.
Cancer :: Philips introduces new MR simulator and CT applications
Royal Philips (NYSE: PHG, AEX: PHI) is introducing advances in its portfolio of leading oncology solutions to help physicians define their targets easily and effectively. Recognizing that console time is at a premium in busy imaging centers, Philips is announcing the availability of its Tumor LOC application on the workstation. The company is also unveiling Panorama 1.0T R/T?the first high field open MR simulator. These technologies are on display at the 48th annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Philadelphia.
Immunity :: Natural compounds block autoimmune response in diabetes, arthritis
Natural compounds derived from a sea anemone extract and a shrub plant have been found to block the autoimmune disease response in type-1 diabetes and rheumatoid arthritis, according to University of California, Irvine researchers.
Cancer :: ‘Hair Again’ Gives Cancer Journey Meaning
“Medicine alone is not enough to get you through cancer,” comments Linda Dibblee, breast cancer survivor and winner of the 2006 Lilly Oncology on Canvas International Art Competition and Exhibition. “You have to stay strong and positive through even the darkest times. Having a channel through which you can release your feelings can help you find strength that you never knew you had. For me, painting became my way of expressing all my thoughts, hopes and frustrations, and I truly believe it played a part in helping me beat cancer.”
Diabetes :: Accurate coding is key to preventing potentially serious health complications associated with insulin overdose
Significant errors in insulin dose can result when blood glucose meters are miscoded according to new clinical study. When persons with diabetes use miscoded blood glucose meters to determine how much insulin to take, significant errors in insulin dose can result that may potentially lead to short- and long-term health complications, according to findings of a new study presented at the Sixth Annual Diabetes Technology Meeting in Atlanta, Georgia.
Colorectal Cancer :: Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
ImClone Systems Incorporated (NASDAQ:IMCL) and Bristol-Myers Squibb Company (NYSE:BMY) today announced results from two randomized Phase III trials of ERBITUX(R) (cetuximab) in patients with metastatic colorectal cancer. These are the first large, randomized studies to examine the impact of ERBITUX treatment on overall survival in colon cancer.